65,437 trials
Kidney Disease, Chronic
Primary: Percentage of Participants With Hemoglobin (Hb) Value Within the Target Range (110 to 120 Grams Per Liter [g/L]) at Baseline — 22.8 Percentage of participants
Hypertension
Primary: 24-hour Urinary Sodium Excretion — 220.58; 198.73; 177.40; 146.18 mmol/24 hours
Acute Otitis Media
Primary: Time to Cessation of Otorrhea — 6.83; 22; 4.94 days
Stroke
Primary: Balance - Measured With the Berg Balance Scale — 46.3; 43.8 units on a scale
Glioblastoma Multiforme
Primary: Percentage of Participants Achieving Progression-Free Survival (PFS) Without Disease Progression or Death at 6 Months — 79.31; 42.59 percentage of participants — p=<0.0001
Diabetes · Diabetes Mellitus, Type 2
Primary: Change From Baseline in HbA1c (Glycosylated Haemoglobin) — -1.85; -1.73 Percent (%) glycosylated haemoglobin
Colon Cancer · Rectal Cancer
Primary: To Determine Overall Objective Response. — 9; 6 participants
Diabetes · Diabetes Mellitus, Type 2
Primary: Change in Glycosylated Haemoglobin (HbA1c) — -1.33; -1.09 percentage of glycosylated haemoglobin
Non Small Cell Lung Cancer · Lung Cancer
Primary: Number of Patients With Pathologic Complete Response Rate — 1; 1; 2; 2 participants
Alzheimer Disease · Dementia · Dementia, Vascular
Primary: Pain Assessment in Advanced Dementia (PAINAD) — 2.20; 2.56 units on a scale
Breast Cancer
Primary: Overall Response Rate — 20 participants
Neuroendocrine Tumors · Metastatic Neuroendocrine Tumors
Primary: Objective Response Rate (ORR) — 13; 12 participants
Alzheimer's Disease · Apathy · Dementia
Primary: Apathy Evaluation Scale Score at 12 Weeks — 38.2; 43.6 units on a scale — p=<0.05
Breast Cancer · Axillary Lymph Node Dissection
Primary: Number and Prevalence of Metastases of Blue Nodes in the ALND Specimen (Nodes Draining the Breast). — 0 participants
Bleeding · Hemorrhage
Primary: INTEM HEPTEM and FIBTEM Test of the ROTEM Coagulation Analyzer — 98; 117; 178; 253 seconds